Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Zelira Therapeutics ( (AU:ZLD) ).
Zelira Therapeutics announced it received a $1,153,000 cash refund under the Australian Federal Government’s R&D Tax Incentive Scheme. This funding is intended to support the company’s clinical development programs and business operations, enhancing its operational capacity and market positioning. The injection of funds will bolster Zelira’s efforts in pipeline product initiatives and essential operations, potentially impacting its stakeholders positively by driving forward its strategic goals in the cannabinoid-based medicine industry.
More about Zelira Therapeutics
Zelira Therapeutics is a global biopharmaceutical company focused on the research, development, and commercialization of clinically validated cannabinoid-based medicines. The company offers a portfolio of proprietary products and is actively developing branded cannabinoid medicines for conditions like insomnia, autism, and chronic pain. Zelira also engages in over-the-counter products in oral and dermatology sectors, generating revenue through various partnerships and commercial endeavors worldwide.
YTD Price Performance: -15.84%
Average Trading Volume: 437
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.71M
Learn more about ZLD stock on TipRanks’ Stock Analysis page.
